Latest News - Moderna
Top Corporates Hub
Moderna
Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions
20.02.2026 05:32
Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S. launch of MNEXT Spike, improved operational efficiency, and disciplined expense controls as key contributors. CEO Stéphane Bancel highlighted that operating expenses fell by 31% year over year, while President Stephen Hoge noted, “MNEXT Spike quickly became our leading product in the U.S.” The leaders
Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions
20.02.2026 05:32
Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S. launch of MNEXT Spike, improved operational efficiency, and disciplined expense controls as key contributors. CEO Stéphane Bancel highlighted that operating expenses fell by 31% year over year, while President Stephen Hoge noted, “MNEXT Spike quickly became our leading product in the U.S.” The leaders
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
19.02.2026 15:30
MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.
Moderna to Present at Upcoming Conferences in March 2026
19.02.2026 12:00
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, on Tuesday, March 3rd at 1:50pm ...
Markets Are in the AI Doldrums. Why Trump’s Iran Posturing Could Change That.
19.02.2026 11:25
Fed meeting minutes put rate hikes back on the table, New York Fed’s tariff research draws administration’s ire, Carvana’s murky outlook disappoints, and more news to start your day.
? The Moderna Flu Shot Drama
19.02.2026 11:15
The Food and Drug Administration agreed Wednesday to review Moderna’s application to make a new seasonal flu shot available, after initially refusing to do so. The back-and-forth reveals increased turmoil within the agency.
Moderna Spikes After FDA’s About-Face on mRNA Flu Vaccine
19.02.2026 05:01
Just last week, the agency rejected Moderna’s initial application, citing flaws in the company’s research design.
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
17.02.2026 12:00
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...
The European Commission Approves Moderna's mNEXSPIKE (mRNA-1283), A New Covid Vaccine, For Active Immunization To Prevent Covid-19 In Individuals Aged 12 Years And Older
17.02.2026 08:10
This marketing authorization follows the positive opinion adopted by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and marks Moderna's third product authorized in the
Moderna Secures Third EU-Authorized Vaccine With mNEXSPIKE, Supporting Protection Against Endemic COVID-19 As European Market Reopens In 2026
17.02.2026 08:09
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
FDA Flu Setback Tests Moderna’s mRNA Pipeline And Regulatory Assumptions
16.02.2026 00:20
FDA issues a surprise refusal to review Moderna's mRNA-based flu vaccine filing, despite earlier agreement on trial design. Decision is described as unprecedented, with no cited safety or efficacy concerns in the application. The vaccine is under review in Europe, Canada, and Australia, while the US process stalls. Moderna, listed as NasdaqGS:MRNA, is best known for its mRNA based Covid 19 vaccine and has been working to extend that platform into seasonal flu and other respiratory diseases...
Is Moderna (MRNA) Pricing Reflecting Potential After Sharp Multi‑Year Share Price Pullback?
15.02.2026 21:08
If you are wondering whether Moderna's current share price reflects its true potential, or if the market is still anchored to its pandemic story, this article will help you unpack what the numbers may indicate about value. At a last close of US$42.23, Moderna's stock shows a 3.0% return over 7 days, 1.0% over 30 days, 36.8% year to date and 28.0% over 1 year, set against a 74.7% decline over 3 years and a 75.8% decline over 5 years. Recent news about Moderna has focused on its position in...
Equities Mixed After CPI Data; Wall Street Sees Worst Week Since November
13.02.2026 21:46
US equity benchmarks ended mixed on Friday as traders evaluated inflation data, capping Wall Street'
Moderna, Inc. Q4 2025 Earnings Call Summary
13.02.2026 21:15
Moby summary of Moderna, Inc.'s Q4 2025 earnings call
Stock market today: Dow, S&P 500, Nasdaq gains fizzle to cap week of sharp losses as AI fears grow
13.02.2026 21:02
Odds of a Fed rate cut in June nudge higher after 'core' consumer inflation comes in at its lowest rate in four years.
Sector Update: Health Care Stocks Advance Late Afternoon
13.02.2026 20:52
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.7% and the S
Moderna Challenges FDA After Flu Shot Review Refusal, 26% Covid Drop
13.02.2026 19:16
Moderna Slams FDA After Flu Shot Review Rejection, 26% Covid Drop
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial ...
13.02.2026 19:01
Despite a significant net loss, Moderna Inc (MRNA) showcases robust cost management and strategic international growth plans.
Health Care Roundup: Market Talk
13.02.2026 17:27
Find insight on Sanofi, Moderna and more in the latest Market Talks covering the health care sector.